UNSPSC 51381801: Fentiazac

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H12ClNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0YHF6E6NLS, chemically known as 5-thiazoleacetic acid, 4-(p-chlorophenyl)-2-phenyl- but generally known as fentiazac, which bears US NIH Compound Identifier 28871. European Medicines Agency schedules Fentiazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07598MIG.

UNSPSC 51381801 Fentiazac, a Commodity code, does not reflect the actual scope of recent state and local procurement activity tagged under it. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which center on fentiazac as a procurement focus. State and local buyers using this code appear to be procuring a broader range of pharmaceutical products and pharmacy benefit management services rather than fentiazac specifically. The issuing bodies span a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (MMCAP, administered through Minnesota). This mix indicates that the code is reaching health-focused local and state jurisdictions as well as multi-jurisdictional procurement vehicles.

Recent activity includes Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023); Texas HHS Commission's RFI seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (response deadline April 3, 2026); and MMCAP's RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with proposals due March 26, 2026. Geographic activity is concentrated in Florida, Texas, and Minnesota, with the MMCAP vehicle extending into Oregon. The mismatch between the code's nominal product (fentiazac) and the actual procurement scope (naloxone, generic pharmaceuticals, pharmacy benefit management) suggests either persistent misclassification by issuing bodies or that this code does not serve as the primary taxonomy entry for pharmaceutical procurement in state and local purchasing systems.